These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 16145414)

  • 21. Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: A randomized, prospective, comparative trial using a urodynamic study.
    Matsukawa Y; Takai S; Funahashi Y; Kato M; Yamamoto T; Gotoh M
    Neurourol Urodyn; 2017 Mar; 36(3):748-754. PubMed ID: 27060991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results of a randomized, double-blind, active-controlled clinical trial with propiverine extended release 30 mg in patients with overactive bladder.
    Leng J; Liao L; Wan B; Du C; Li W; Xie K; Shen Z; Xu Z; Wu S; Fang Z; Ma L; Han S; Feustel C; Yang Y; Madersbacher H
    BJU Int; 2017 Jan; 119(1):148-157. PubMed ID: 27087507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction.
    Ichihara K; Masumori N; Fukuta F; Tsukamoto T; Iwasawa A; Tanaka Y
    J Urol; 2015 Mar; 193(3):921-6. PubMed ID: 25254938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
    Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
    BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects.
    MacDonald R; Wilt TJ; Howe RW
    BJU Int; 2004 Dec; 94(9):1263-70. PubMed ID: 15610102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence.
    Madersbacher H; Halaska M; Voigt R; Alloussi S; Höfner K
    BJU Int; 1999 Oct; 84(6):646-51. PubMed ID: 10510109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension.
    Chung BH; Hong SJ
    BJU Int; 2006 Jan; 97(1):90-5. PubMed ID: 16336335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction.
    Füllhase C; Soler R; Gratzke C; Brodsky M; Christ GJ; Andersson KE
    BJU Int; 2010 Jul; 106(2):287-93. PubMed ID: 19888972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis.
    Kirby RS; Quinn S; Mallen S; Jensen D
    Int J Clin Pract; 2004 Jan; 58(1):6-10. PubMed ID: 14994963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pharmacological evaluation of efficacy and safety of propiverine hydrochloride in patients of overactive bladder--relationship between urodynamic observation and propiverine pharmacokinetics--].
    Sugiyama T; Shimizu N; Hashimoto K; Yoshioka N; Hanai T; Matsumoto S; Uemura H
    Nihon Hinyokika Gakkai Zasshi; 2005 Nov; 96(7):670-7. PubMed ID: 16363652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cardura monotherapy versus combination therapy of cardura and tolterodine L-tartrate tablets for II° ? benign prostatic hyperplasia with overactive bladder].
    Wang YY; Shi GW; He JY; Zhang YB
    Zhonghua Nan Ke Xue; 2013 Dec; 19(12):1099-102. PubMed ID: 24432622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Multicenter Study Group.
    Fawzy A; Vashi V; Chung M; Dias N; Gaffney M
    Urology; 1999 Feb; 53(2):329-35. PubMed ID: 9933049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
    Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
    Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravesical prostatic protrusion can predict therapeutic response to silodosin in male patients with lower urinary tract symptoms.
    Matsukawa Y; Ishida S; Majima T; Funahashi Y; Sassa N; Kato M; Yoshino Y; Gotoh M
    Int J Urol; 2017 Jun; 24(6):454-459. PubMed ID: 28370376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
    Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S
    BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: Results from a randomized pilot study.
    Sakalis V; Sfiggas V; Vouros I; Salpiggidis G; Papathanasiou A; Apostolidis A
    Int J Urol; 2018 Aug; 25(8):737-745. PubMed ID: 30008188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Chapple C; Herschorn S; Abrams P; Sun F; Brodsky M; Guan Z
    Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'.
    Lee KS; Lee HW; Choo MS; Paick JS; Lee JG; Seo JT; Lee JZ; Lee YS; Yoon H; Park CH; Na YG; Jeong YB; Lee JB; Park WH
    BJU Int; 2010 Jun; 105(11):1565-70. PubMed ID: 19912183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
    Djavan B; Marberger M
    Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.